OverviewSuggest Edit

JanOne (formerly known as ARCA) is a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Its first drug candidate is a treatment for the peripheral arterial disease (PAD), a condition that can cause severe pain.

TypePublic
Founded2019
HQLas Vegas, NV, US
Websitejanone.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2019)208(+36%)
Revenue (FY, 2019)$35.1 M(-4%)
Share Price (Nov 2021)$5.8
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at JanOne

Tony Isaac

Tony Isaac

Chief Executive Officer and Director
Cyndy Janzig

Cyndy Janzig

Director of Human Resources
Dennis Gao

Dennis Gao

Director
Richard D. Butler

Richard D. Butler

Director
Virland A. Johnson

Virland A. Johnson

Chief Financial Officer
Nael Hajjar

Nael Hajjar

Director
Show more

JanOne Office Locations

JanOne has an office in Las Vegas
Las Vegas, NV, US (HQ)
325 E Warm Springs Rd #102
Show all (1)

JanOne Financials and Metrics

JanOne Revenue

JanOne's revenue was reported to be $35.1 m in FY, 2019
USD

Revenue (Q2, 2020)

4.0m

Gross profit (Q2, 2020)

1.0m

Gross profit margin (Q2, 2020), %

26.1%

Net income (Q2, 2020)

(2.4m)

EBIT (Q2, 2020)

(2.3m)

Market capitalization (12-Nov-2021)

16.6m

Closing stock price (12-Nov-2021)

5.8

Cash (27-Jun-2020)

883.0k

EV

23.4m
JanOne's current market capitalization is $16.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

126.7m114.3m129.1m130.9m111.8m103.6m41.5m36.8m35.1m

Revenue growth, %

(15%)(7%)

Cost of goods sold

89.9m86.4m95.2m74.9m28.4m25.7m27.3m

Gross profit

36.7m28.0m33.9m28.7m13.1m11.1m7.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2017Q1, 2017Q2, 2018Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

32.9m35.9m29.4m29.3m29.0m30.4m32.3m33.5m33.5m33.2m33.6m27.5m30.2m27.4m25.3m24.8m23.2m25.8m25.5m8.9m8.4m6.3m7.6m9.8m8.5m4.0m

Cost of goods sold

23.2m25.8m21.8m21.8m22.3m22.5m23.8m24.4m19.2m18.3m17.2m17.1m17.1m6.5m6.2m5.1m5.7m7.2m7.0m3.0m

Gross profit

9.6m10.1m7.6m7.6m6.7m7.9m8.5m9.1m6.2m6.4m6.0m8.7m8.4m2.4m2.2m1.1m1.9m2.6m1.5m1.0m

Gross profit Margin, %

29%28%26%26%23%26%26%27%24%26%26%34%33%27%26%18%25%26%17%26%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.4m3.2m1.9m3.5m3.5m968.0k3.3m1.2m481.0k

Accounts Receivable

7.4m6.3m12.3m10.5m10.0m5.8m6.6m

Prepaid Expenses

1.4m1.3m622.0k761.0k506.0k617.0k356.0k

Inventories

18.5m17.3m16.7m16.3m762.0k801.0k1.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

4.5m4.7m4.0m3.7m2.8m3.9m2.7m2.1m2.9m2.5m2.9m3.6m3.6m1.7m2.3m2.2m809.0k191.0k2.0m2.1m413.0k652.0k1.4m638.0k837.0k883.0k

Accounts Receivable

9.4m8.2m6.1m6.2m7.3m6.8m9.3m10.8m11.0m6.7m8.8m8.8m12.0m5.9m6.0m4.6m4.9m5.9m4.0m3.3m

Prepaid Expenses

1.2m1.3m1.7m2.5m2.2m1.0m1.3m1.5m1.1m1.1m675.0k2.3m891.0k347.0k1.3m613.0k860.0k854.0k315.0k845.0k

Inventories

16.4m19.0m20.3m21.1m20.5m14.4m14.0m15.2m16.3m15.6m16.3m15.3m15.9m13.2m12.6m11.2m1.2m1.1m975.0k1.0m1.7m1.3m1.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

4.7m(4.5m)3.6m795.0k(3.9m)(1.8m)(378.0k)(5.6m)(12.0m)

Depreciation and Amortization

1.3m1.2m1.4m1.4m1.3m1.3m2.1m4.0m4.1m

Inventories

(1.9m)1.2m620.0k(620.0k)442.0k264.0k(41.0k)(546.0k)

Accounts Payable

(471.0k)491.0k1.6m999.0k59.0k(2.1m)1.7m5.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2017Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

2.7m4.5m(77.0k)(628.0k)(1.8m)129.0k855.0k2.1m1.1m1.7m2.2m(2.0m)(1.5m)(1.7m)(630.0k)(2.8m)1.9m3.9m4.5m(1.5m)(2.9m)(2.0m)(3.4m)(5.4m)(2.3m)(4.7m)

Depreciation and Amortization

667.0k981.0k303.0k609.0k907.0k337.0k680.0k1.0m334.0k676.0k1.0m330.0k648.0k936.0k325.0k634.0k302.0k609.0k1.1m994.0k2.0m1.0m2.0m3.0m1.0m2.0m

Inventories

240.0k(2.4m)(1.8m)(2.7m)(2.1m)2.9m3.2m2.0m447.0k(691.0k)134.0k68.0k544.0k385.0k1.5m801.0k3.1m3.7m5.1m(389.0k)(340.0k)(172.0k)(210.0k)(919.0k)35.0k(481.0k)

Accounts Payable

1.8m3.3m2.4m1.7m1.4m1.3m1.4m3.4m(417.0k)(57.0k)383.0k1.3m1.5m301.0k1.6m744.0k(1.1m)(1.6m)(4.5m)211.0k1.0m520.0k783.0k708.0k(749.0k)(1.5m)
USDQ2, 2012

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

3.1 x
Show all financial metrics

JanOne Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

JanOne Online and Social Media Presence

Embed Graph

JanOne News and Updates

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

LAS VEGAS, July 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service...

JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing

LAS VEGAS, June 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of Avania as its regulatory partner in the upcoming...

JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101

LAS VEGAS, June 8, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the successful completion of Current Good Manufacturing Practices...

JanOne Prices $6.0 Million Common Stock Offering

LAS VEGAS, Jan. 29, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with...

JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

LAS VEGAS, Sept. 24, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started production of JAN101 under Current...

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease

LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has issued its September 2020 Shareholder Letter....
Show more

JanOne Blogs

ARCA Recycling, a Subsidiary of JanOne Inc., Launches Two Recycling Programs in California in Effort to Reduce GHG Emissions

Minneapolis – October 27, 2021 – ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), launched two new appliance recycling programs in Northern California, with a focus on decreasing the release of greenhouse gas (GHG) and ozone-depleting emissions into the atmosphere. The p…

ARCA Recycling, a Subsidiary of JanOne Inc., Sees Major Increase in Appliance Replacement Contracts, Estimated to Push Revenue of Replacement Programs to Nearly $20 Million, in Addition to Recycling Business

MINNEAPOLIS, Oct. 19, 2021 /PRNewswire/ — ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), has seen major growth in its appliance replacement programs throughout the past 12 months, with the addition of new contracts signed this year that total more than $3 million. It i…

ARCA Recycling, a Subsidiary of JanOne Inc., Opens Recycling Center in Michigan to Support New Multi-Year Contracts Totaling Millions in Revenue

Minneapolis – October 12, 2021 – ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), recently opened a new recycling facility in Grand Rapids, Michigan to support its growth in the state. ARCA was recently awarded multiple contracts to provide appliance recycling services f…

JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101

JanOne’s management is encouraged regarding Recent Discussions on Potential Phase 2b Trial Endpoints and Possible Regulatory Routes for JAN101 as Treatment for Peripheral Artery Disease (PAD) LAS VEGAS, [DATE], 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company that focuses on the development …

JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drug…

JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

World leader in addiction science joins team of experts in diseases and disorders that cause chronic pain LAS VEGAS, June 15, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving p…
Show more

JanOne Frequently Asked Questions

  • When was JanOne founded?

    JanOne was founded in 2019.

  • Who are JanOne key executives?

    JanOne's key executives are Tony Isaac, Cyndy Janzig and Dennis Gao.

  • How many employees does JanOne have?

    JanOne has 208 employees.

  • What is JanOne revenue?

    Latest JanOne annual revenue is $35.1 m.

  • What is JanOne revenue per employee?

    Latest JanOne revenue per employee is $168.7 k.

  • Who are JanOne competitors?

    Competitors of JanOne include Assertio, EMS Pharma and Livzon Pharmaceutical Group.

  • Where is JanOne headquarters?

    JanOne headquarters is located at 325 E Warm Springs Rd #102, Las Vegas.

  • Where are JanOne offices?

    JanOne has an office in Las Vegas.

  • How many offices does JanOne have?

    JanOne has 1 office.